3month7day-8Today, CITIC Securities “New Pharmaceutical Cycle, Spring Brings Bountiful Blossoms”2023The annual Healthcare Industry Spring Strategy Conference was successfully held in Shanghai. This strategy conference focused on industry trends and hotspots such as the domestic independent and controllable pharmaceutical supply chain, major healthcare infrastructure and innovative medical devices, the harvest period of high-quality generic and branded drugs in China, post-pandemic recovery and epidemic prevention innovation. It invited many entrepreneurs or executives from related listed companies, industry experts and scholars, as well as seasoned investors, aiming to jointly discuss and look ahead to how to grasp the core asset layout direction in the new cycle era of the pharmaceutical industry.
Frost & SullivanFrost & SullivanMao Hua, Partner and Managing Director of Frost & Sullivan's Greater China Region, was invited to attend the event and delivered a keynote speech on "Development Trends and Technological Evolution in the Innovative Medicines Industry".
Mao Hua pointed out, monoclonal antibodies, bispecific antibodies,ADCLarge molecule drugs such as antibody fusion proteins have become an important area in new drug research and development. Clinical trials of innovative therapies represented by cell therapy, gene therapy, nucleic acid drugs, and oncolytic viruses continue to increase, accounting for an increasingly higher proportion in the clinical development of new drugs. Recently3The annual proportion has reached3.8%.
However, at the same time, due to China's weak basic medical research capabilities, the lack of historical accumulation in new drug development, the immaturity of the industrial chain, and the lag in regulatory oversight, there has been a clustering of new drug R&D activities in China. This has led to serious homogenization and, to some extent, has caused a waste of resources.
"By developing new targets, avoiding target overcrowding, iterating and upgrading R&D technologies, and Transforming drug development strategies and other methods to create differentiated product pipelines is the key for pharmaceutical companies to break through in fierce competition." Mao Hua said.
Subsequently, Mao Hua briefly analyzed the development trends of the innovative drug industry. He stated that the innovative drug industry will exhibit the following three development trends:1The domestic market is shifting towards overseas markets;2)BiotechreachBiopharma companyThe transformation;3)in LicensereachLicense-out of the MainlandTransformation.
In recent years, factors such as enhanced R&D capabilities for innovative drugs, great potential in overseas markets, gradual integration at home and abroad, and domestic pressure to reduce prices for innovative drugs have driven Chinese pharmaceutical companies to go global and actively explore international market territories. Data shows that in the past five years, the number of clinical trials conducted overseas by Chinese pharmaceutical companies has generally shown an increasing trend.2021The number of companies making overseas clinical trial plans for the year2018The annual growth is about double. As Chinese pharmaceutical companies continue to strengthen their strategic deployment in overseas markets and compete to conduct overseas clinical trials, the overseas market will become an important driving force for corporate growth in the future.
On the other hand, driven by factors such as desire to drive growth, industrial environmental impact, good market prospects, and continuously improving commercial capabilities, more and moreBiotechThe company has embarked onBiopharma companyThe path to progress. Hong Kong Stock Market18ARevenue generated since the launch of the fifth batch of STAR Market listingsBiotechThe number is increasing year by year. at present57Home-listedBiotechmiddle,2022yearH1Existing4The home stock successfully turned losses into profits “and turned red-hot in Hong Kong shares”18AAnd the fifth sector of science, technology and innovationBiotechThe profitability is strengthening.
In addition, as the domestic innovation drug ecosystem gradually takes shape, biotech companies are continuouslyLicense-out of the MainlandTransactions bring domestic technology abroad, and by collaborating with multinational enterprises, we can better participate in global competition.License-out of the MainlandCapable of helping enterprises reduce R&D risks, expand sales reach, and optimize cash flow, ChinaLicense-out of the MainlandThe trading volume has remained high in recent years. Mao Hua pointed out that in the future, pharmaceutical companies can continuously optimizeLicense-out of the MainlandStrategy, opening up broader global markets to help enterprises achieve value growth.
About Frost & Sullivan's Healthcare Practice
The Healthcare Practice of Frost & Sullivan has professional analytical capabilities and extensive project experience in the life sciences sector. Leveraging the global think tank resources of Frost & Sullivan and its cross-industry business development platform in Greater China, Frost & Sullivan Healthcare has unique core advantages in investment and financing services for the healthcare industry. Frost & Sullivan Healthcare has a wide range of corporate clients in China and in the past20In the year, a vast customer network was established, and a wealth of project experience in various medical sub-fields was accumulated.
Project types include Knowledge Center projects (in-depth content, promotional activities).Pre-IPO financingprojectDCF modelValuation, Business Plan Services),IPO listingWe provide listed projects (industry consulting, clinical audits, fundraising and investment writing), market research, market value management, strategic consulting, etc. We also cooperate with well-known domestic and international information platforms and investment and financing institutions to offer one-stop solutions for enterprises in specialized sub-fields such as pharmaceuticals and medical devices. Our services have received wide attention from investors.
